Scientific Program - Dementia

Print
Please see below the CONy Scientific Program. Please click on the appropriate section (ordered by ABC) to view the relevant program. Please note that the program and timing is subject to change. To view the program timetable, please click here
 
 
Section Heads: Tomasz Gabryelewicz, Poland & Lefkos Middleton, UK
FRIDAY MARCH 23, 2018 HALL D
08:45-10:55
SESSION 17 | DEMENTIA: RISK FACTORS
  Chairs: Nataliya Pryanykova, Ukraine & Ricardo Nitrini, Brazil
08:45-09:50
Does general anesthesia increase the risk of dementia?
Capsule:
Anecdotal evidence and limited case series report exacerbation of cognition following surgery under general anesthetics. Is this observation correct and should elderly individuals be warned against it?
08:45-08:55 Host: Isabel Santana, Portugal
08:55-09:15
Pro: Magda Tsolaki, Greece
09:15-09:35 Con: Lawrence Honig, USA
09:35-09:50 Discussion and Rebuttals
   
09:50-10:35
Is obstructive sleep apnea an important risk factor for dementia?
Capsule: Obstructive sleep apnea (OSA) causes brain anoxia, which theoretically can exacerbate damage to the vulnerable brain. Is this of practical importance and should patients be screened for OSA?
09:50-10:00 Host: Luiza Spiru, Romania
10:00-10:20 Pro: Giancarlo Logroscino, Italy
10:20-10:40 Con: Lawrence Honig, USA
10:40-10:55 Discussion and Rebuttals
   
10:55-11:10 Coffee Break
   
11:10-13:10 SESSION 18 | ALZHEIMER'S DISEASE (AD): DIAGNOSIS AND THERAPY
  Chair: Homa Ebrahimi, Iran
11:10-12:15
Can the diagnosis of AD be made solely on biomarker evidence?
Capsule: Is the presence of CSF and/or imaging biomarker evidence of abnormal brain load of amyloid and tau sufficient for the diagnosis of AD, even in the absence of cognitive decline?
11:10-11:20
Host: David Knopman, USA
11:20-11:40 Pro: Giancarlo Logroscino, Italy
11:40-12:00 Con: Lefkos Middleton, UK
12:00-12:15 Discussion and Rebuttals
   
12:15-13:20
Should agitation in AD be treated with antipsychotics?
Capsule:
Agitation in AD patients is an ominous sign, frequently leading to nursing home placement. Is it justified to treat patients with neuroleptic drugs in spite of their significant adverse effects?
12:15-12:25
Host: Tomasz Gabryelewicz, Poland
12:25-12:45 Pro: Daniel Drubach, USA
12:45-13:05 Con: Pasquale Calabrese, Switzerland
13:05-13:20 Discussion and Rebuttals
   
13:20-14:20 Industry Sponsored Symposium (Not for CME) – HALL A
   
14:20-15:05 Lunch Break
   
15:05-16:55
SESSION 19 | AD: CONCEPTS
  Chair: Mee Young Park, South Korea
15:05-16:00 Is amyloid deposition a non-specific manifestation of aging?
Capsule: Beta amyloid deposition is required for a pathological diagnosis of AD. Yet, many elderly people have such deposits but are cognitively normal. Can amyloid be simply a manifestation of aging, like baldness or skin wrinkles?
15:05-15:15
Host: Lefkos Middleton, UK
15:15-15:30 Pro: Panteleimon Giannakopoulos, Switzerland
15:30-15:45 Con: Marios Politis, UK
15:45-16:00 Discussion and Rebuttals
   
16:00-16:55 The term "Alzheimer's disease" should be dropped as it is impeding future research
Capsule: For 50 years, the term AD was reserved for cases with presenile dementia, but the term has been expanded to replace the term "sentile dementia". Is this terminology shift helpful?
16:00-16:10
Host: Robert Perneczky, UK
16:10-16:25 Pro: Amos Korczyn, Israel
16:25-16:40 Con: David Knopman, USA
16:40-16:55 Discussion and Rebuttals
16:55-17:10
Coffee Break
   
17:10-19:00 SESSION 20 | DEMENTIA - TREATMENT
  Chairs: Judith Aharon, Israel
17:10-18:05 Does cognitive stimulation have value in the treatment of mild cognitive impairment (MCI) and early dementia?
Capsule:
Cognitive stimulation has been suggested as an important disease modifying strategy in people with early cognitive decline including engagement in crossword puzzles, bridge playing, and computer-based excercises. But are these really effective? What is the evidence?
17:10-17:20
Host: Dorota Religa, Sweden
17:20-17:35
Pro: Michael Geschwind, USA
17:35-17:50 Con: Roger Bullock, UK
17:50-18:05 Discussion and Rebuttals
   
18:05-19:00 Is inflammation a valid target for intervention in AD?
Capsule:
Inflammatory processes occur in any damaged tissue, and are seen in AD brains as activated microglia and astrocytes, as well as elevated cytokine and chemokine levels. Are these detrimental and should they be manipulated?
18:05-18:15
Host: Maria Barcikowska, Poland
18:15-18:30
Pro: Agneta Nordberg, Sweden
18:30-18:45 Con: Panteleimon Giannakopoulos, Switzerland
18:45-19:00 Discussion and Rebuttals
   
SUNDAY MARCH 25, 2018 HALL C
11:00-13:00
SESSION 41 | DEMENTIA
  Chairs: Michal Prendecki, Poland
11:00-11:55
Is traumatic brain injury a risk for dementia?
11:00-11:10 Host: Babak Tousi, USA
11:10-11:25
Pro: Dan Perl, USA
11:25-11:40 Con: Daniel Drubach, USA
11:40-12:00 Discussion and Rebuttals
   
12:00-13:00
The clinical criteria of NPH are sensitive and predictive of response to shunting
 Capsule:
Not all patients shunted for NPH can improve after surgery. Patient's clinical profile, shunt functioning, quality of surgery may contribute. Predictors for improvement are often misleading. Clinical, physiological measurement, and imaging factors can present with different pros and cons.
12:00-12:10 Host: Marek Czonsnyka, UK
12:10-12:25 Pro: Ullrich Wuellner, Germany
12:25-12:40 Con: Carsten Wikkelso, Sweden
12:40-13:00 Discussion and Rebuttals